Lynn Weekes to leave NPS after two decades at the helm
The Board of NPS MedicineWise has announced that Dr Lynn Weekes AM has resigned as the organisation’s CEO after “20 years of exceptional leadership”.
Dr Weekes was the inaugural CEO of NPS MedicineWise, leading the organisation since its establishment in 1998 as the National Prescribing Service—the lead implementation body for quality use of medicines and medical tests evolving from the National Medicines Policy and working independently of government.
Dr Weekes (pictured), who will remain in the role till the end of June 2018, originally practised as a pharmacist, practicing in the hospital and research fields.
She has contributed significantly through research and her professional career to the development of quality use of medicines resources and services in Australia, the NPS said in a statement.
Peter Turner, chair of NPS MedicineWise, said Dr Weekes has been an exemplary health leader and a champion for improved health care and decision making.
“Lynn’s contributions to the community through quality use of medicines were formally recognised in 2013 when she was appointed a Member of the Order of Australia,” he said.
“Anyone who has worked with her understands how integral she has been to embedding quality use of medicines and other health technologies into the Australian health system.
“Her leadership, collaborative style and deep expertise over the past two decades has brought to life the original vision for quality use of medicines and cemented this as a cornerstone of sustainable and high quality healthcare.”
“Lynn has been instrumental in ensuring NPS MedicineWise remains innovative and responsive to the needs of health professionals, service providers, industry, regulators, consumers and the community, and a thriving and successful organisation.”
Prior to her role with NPS MedicineWise, Dr Weekes was executive officer of NSW Therapeutic Assessment Group where she was involved in drug use practice, evaluation and policy.
The NPS MedicineWise board will begin searching for a new chief executive in early 2018.